E.U. Panel Backs Novartis' Mock-up Pandemic Flu Vaccine

by Medindia Content Team on  February 25, 2007 at 10:37 AM Drug News
RSS Email Print This Page Comment
Font : A-A+

E.U. Panel Backs Novartis' Mock-up Pandemic Flu Vaccine
Europe's main medical regulator said it has adopted a positive opinion recommending the granting of a marketing authorization for Focetria, from Novartis AG (NVS) Vaccines and Diagnostics unit.

Focetria is a mock-up pandemic influenza vaccine, intended for the prevention of influenza during an officially declared pandemic situation, once the pandemic viral strain has been included. It is the second mock-up pandemic influenza vaccine to receive a positive opinion from the Committee.

Mock-up pandemic influenza vaccines are approved only for use in a declared pandemic influenza situation. The objective is to have a marketing authorization in place that can be changed quickly in the event of a pandemic to include the virus strain responsible, once it has been identified.

Source: Bio-Bio Technology
SRM

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Flu Swine Flu 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive